Furthermore, targeting USP7 leads to tumor cell elimination in various preclinical models, while also enhancing the cytotoxicity of CAR-T cells against TP53-mutant relapsed/refractory (r/r) DLBCL PDCs. Here, USP7 is linked to diffuse large B-cell lymphoma.